Folic Acid Supplementation to Prevent Neural Tube Defects: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
- PMID: 37526714
- DOI: 10.1001/jama.2023.9864
Folic Acid Supplementation to Prevent Neural Tube Defects: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Abstract
Importance: Neural tube defects are among the most common birth defects in the US.
Objective: To review new evidence on the benefits and harms of folic acid supplementation for the prevention of neural tube defects to inform the US Preventive Services Task Force.
Evidence review: Sources included PubMed, Cochrane Library, Embase, and trial registries from July 1, 2015, through July 2, 2021; references; and experts, with surveillance through February 10, 2023. Two investigators independently reviewed English-language randomized studies and nonrandomized cohort studies in very highly developed countries that focused on the use of folic acid supplementation for the prevention of neural tube defect-affected pregnancies; methodological quality was dually and independently assessed.
Findings: Twelve observational studies (reported in 13 publications) were eligible for this limited update (N = 1 244 072). Of these, 3 studies (n = 990 372) reported on the effect of folic acid supplementation on neural tube defects. For harms, 9 studies were eligible: 1 randomized clinical trial (n = 431) reported on variations in twin delivery, 7 observational studies (n = 761 125) reported on the incidence of autism spectrum disorder, and 1 observational study (n = 429 004) reported on maternal cancer. Two cohort studies and 1 case-control study newly identified in this update reported on the association between folic acid supplementation and neural tube defects (n = 990 372). One cohort study reported a statistically significant reduced risk of neural tube defects associated with folic acid supplementation taken before pregnancy (adjusted relative risk [aRR], 0.54 [95% CI, 0.31-0.91]), during pregnancy (aRR, 0.62 [95% CI, 0.39-0.97]), and before and during pregnancy (aRR, 0.49 [95% CI, 0.29-0.83]), but this association occurred for only the later of 2 periods studied (2006-2013 and not 1999-2005). No other statistically significant benefits were reported overall. No study reported statistically significant harms (multiple gestation, autism, and maternal cancer) associated with pregnancy-related folic acid exposure.
Conclusions and relevance: New evidence from observational studies provided additional evidence of the benefit of folic acid supplementation for preventing neural tube defects and no evidence of harms related to multiple gestation, autism, or maternal cancer. The new evidence was consistent with previously reviewed evidence on benefits and harms.
Similar articles
-
Folic Acid Supplementation to Prevent Neural Tube Defects: A Limited Systematic Review Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2023 Aug. Report No.: 22-05302-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2023 Aug. Report No.: 22-05302-EF-1. PMID: 37552787 Free Books & Documents. Review.
-
Folic Acid Supplementation for the Prevention of Neural Tube Defects: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2017 Jan 10;317(2):190-203. doi: 10.1001/jama.2016.19193. JAMA. 2017. PMID: 28097361 Review.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Folic acid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force.Ann Intern Med. 2009 May 5;150(9):632-9. doi: 10.7326/0003-4819-150-9-200905050-00010. Ann Intern Med. 2009. PMID: 19414843 Review.
-
Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies.J Obstet Gynaecol Can. 2015 Jun;37(6):534-52. doi: 10.1016/s1701-2163(15)30230-9. J Obstet Gynaecol Can. 2015. PMID: 26334606 English, French.
Cited by
-
The DNA demethylase TET1 modifies the impact of maternal folic acid status on embryonic brain development.EMBO Rep. 2024 Nov 22. doi: 10.1038/s44319-024-00316-1. Online ahead of print. EMBO Rep. 2024. PMID: 39578553
-
The unique presentation of the relationship between red blood cell folate and appendicular skeletal muscle mass: a cross-sectional study.Sci Rep. 2024 Nov 8;14(1):27263. doi: 10.1038/s41598-024-76693-3. Sci Rep. 2024. PMID: 39516506 Free PMC article.
-
Supplementation with Folic Acid or 5-Methyltetrahydrofolate and Prevention of Neural Tube Defects: An Evidence-Based Narrative Review.Nutrients. 2024 Sep 18;16(18):3154. doi: 10.3390/nu16183154. Nutrients. 2024. PMID: 39339754 Free PMC article. Review.
-
Epigenetic regulation by TET1 in gene-environmental interactions influencing susceptibility to congenital malformations.bioRxiv [Preprint]. 2024 Jul 8:2024.02.21.581196. doi: 10.1101/2024.02.21.581196. bioRxiv. 2024. PMID: 39026762 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
